Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis
- Jill P Buyon, MD
Jill P Buyon, MD
- Professor of Medicine
- New York University School of Medicine
- Section Editors
- Thomas JA Lehman, MD
Thomas JA Lehman, MD
- Section Editor — Pediatric Rheumatology
- Professor of Clinical Pediatrics
- Cornell University Medical College
- John K Triedman, MD
John K Triedman, MD
- Section Editor — Pediatric Cardiology
- Professor of Pediatrics
- Harvard Medical School
- Joseph A Garcia-Prats, MD
Joseph A Garcia-Prats, MD
- Section Editor — Neonatology
- Professor of Pediatrics
- Baylor College of Medicine
Neonatal lupus (NL) is an autoimmune disease that is passively transferred from the mother to the fetus. The major manifestations are cardiac and cutaneous findings. The most serious complication of NL is complete heart block (approximately 20 percent have an associated cardiomyopathy at the initial diagnosis or develop it later [1,2]). In this topic review, the cardiac manifestations of NL are referred to as cardiac-NL and can include any degree of block (referred to as congenital heart block [CHB]) that may or may not be accompanied by extranodal disease such as valvular abnormalities, endocardial fibroelastosis, and/or dilated cardiomyopathy. Occasionally, those manifestations may occur in the absence of heart block.
This topic reviews the epidemiology, pathogenesis, clinical manifestations, and diagnosis of NL. The management and outcomes of NL are discussed in greater detail separately. Pregnancy in women with systemic lupus erythematosus (SLE) and diagnosis and management of fetal arrhythmias are also reviewed elsewhere. (See "Neonatal lupus: Management and outcomes" and "Pregnancy in women with systemic lupus erythematosus" and "Overview of the general approach to diagnosis and treatment of fetal arrhythmias".)
The cardiac manifestations of NL (cardiac-NL), which most commonly involve injury to the conduction system (congenital heart block [CHB]), with complete atrioventricular (AV) block being the most characteristic, occur in approximately 2 percent of offspring of women who have antibodies to Ro/SSA (Sjögren syndrome type A antigen) and/or La/SSB (Sjögren syndrome type B antigen) [3-8]. NL is responsible for 80 to 95 percent of all cases of congenital complete heart block in the absence of structural defects diagnosed in utero or in the neonatal period [9,10]. NL is a much less common cause of heart block presenting after the neonatal period (5 percent in one study) . The risk of developing cutaneous manifestations of NL is 7 to 16 percent in offspring of anti-Ro- and anti-La-positive mothers [5,7] but is also sometimes associated with antibodies to ribonucleoprotein (RNP) .
NL is associated with these specific autoantibodies (Ro/SSA, La/SSB) independent of maternal disease. While some mothers may have systemic lupus erythematosus (SLE) and/or Sjögren syndrome, in many other cases, the mother is totally asymptomatic . Approximately one-half of mothers with these autoantibodies who do not have other evidence of autoimmune disease at the time of the baby's birth later develop autoimmune disease (more commonly Sjögren syndrome than SLE) . (See 'Pathogenesis' below.)
The prevalence of anti-Ro/SSA antibodies was initially reported as 0.2 to 0.72 percent in female blood donors  and, more recently, as 0.86 percent in healthy females in the general population (this may be an underestimation since a less reliable test for anti-Ro/SSA was used for initial screening) . For patients with SLE, the estimated prevalence of this antibody is 40 percent  and in those with SS between 60 to 100 percent . The population prevalence of CHB in Finland was reported as 1 in 17,000 live births , with the highest annual estimate at 1:6500. However, this may be an underestimation since only children with pacemakers were included and fetal deaths were not captured. If the true prevalence of anti-Ro/SSA approaches 0.9 percent and CHB occurs in 2 percent and recurs in 18 percent, this could yield approximately 600 to 700 cases per year in the United States based upon the 2012 National Vital Statistics System data of 3,952,841 births. These results are consistent with a crude estimate based upon the 0.5 percent prevalence of anti-Ro/SSA antibodies in asymptomatic pregnant women and the rate of CHB of 1 in 15,000 to 1 in 22,000 livebirths [17,18].
- Izmirly PM, Saxena A, Kim MY, et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 2011; 124:1927.
- Izmirly PM, Saxena A, Sahl SK, et al. Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system. Ann Rheum Dis 2016; 75:1161.
- Brucato A, Cimaz R, Caporali R, et al. Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. Clin Rev Allergy Immunol 2011; 40:27.
- Brucato A, Frassi M, Franceschini F, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001; 44:1832.
- Cimaz R, Spence DL, Hornberger L, Silverman ED. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 2003; 142:678.
- Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM, et al. Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum 2004; 50:3187.
- Friedman DM, Kim MY, Copel JA, et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 2008; 117:485.
- Brito-Zerón P, Izmirly PM, Ramos-Casals M, et al. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 2015; 11:301.
- Buyon JP, Clancy RM, Friedman DM. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nat Clin Pract Rheumatol 2009; 5:139.
- Jaeggi ET, Hamilton RM, Silverman ED, et al. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years. J Am Coll Cardiol 2002; 39:130.
- Provost TT, Watson R, Gammon WR, et al. The neonatal lupus syndrome associated with U1RNP (nRNP) antibodies. N Engl J Med 1987; 316:1135.
- Rivera TL, Izmirly PM, Birnbaum BK, et al. Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus. Ann Rheum Dis 2009; 68:828.
- Fritzler MJ, Pauls JD, Kinsella TD, Bowen TJ. Antinuclear, anticytoplasmic, and anti-Sjogren's syndrome antigen A (SS-A/Ro) antibodies in female blood donors. Clin Immunol Immunopathol 1985; 36:120.
- Satoh M, Chan EK, Ho LA, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012; 64:2319.
- Keogan M, Kearns G, Jefferies CA. Extractable nuclear antigens and SLE: Specificity and role in disease pathogenesis. In: Systemic Lupus Erythematosus, 5th ed., Lahita RG, Tsokos G, Buyon J, Koike T (Eds), Academic Press, San Diego 2011. p.259.
- Sirén MK, Julkunen H, Kaaja R. The increasing incidence of isolated congenital heart block in Finland. J Rheumatol 1998; 25:1862.
- Buyon JP, Kim MY, Copel JA, Friedman DM. Anti-Ro/SSA antibodies and congenital heart block: necessary but not sufficient. Arthritis Rheum 2001; 44:1723.
- Michaëlsson M, Engle MA. Congenital complete heart block: an international study of the natural history. Cardiovasc Clin 1972; 4:85.
- Llanos C, Izmirly PM, Katholi M, et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum 2009; 60:3091.
- Izmirly PM, Llanos C, Lee LA, et al. Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis Rheum 2010; 62:1153.
- Clancy RM, Neufing PJ, Zheng P, et al. Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest 2006; 116:2413.
- Miranda-Carús ME, Askanase AD, Clancy RM, et al. Anti-SSA/Ro and anti-SSB/La autoantibodies bind the surface of apoptotic fetal cardiocytes and promote secretion of TNF-alpha by macrophages. J Immunol 2000; 165:5345.
- Clancy R, Molad Y, Kapur R, et al. Histologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathogenesis of congenital heart block (abstract). Arthritis Rheum 2002; 46:S394.
- Clancy RM, Askanase AD, Kapur RP, et al. Transdifferentiation of cardiac fibroblasts, a fetal factor in anti-SSA/Ro-SSB/La antibody-mediated congenital heart block. J Immunol 2002; 169:2156.
- Garcia S, Nascimento JH, Bonfa E, et al. Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts. J Clin Invest 1994; 93:718.
- Xiao GQ, Hu K, Boutjdir M. Direct inhibition of expressed cardiac l- and t-type calcium channels by igg from mothers whose children have congenital heart block. Circulation 2001; 103:1599.
- Karnabi E, Qu Y, Mancarella S, Boutjdir M. Rescue and worsening of congenital heart block-associated electrocardiographic abnormalities in two transgenic mice. J Cardiovasc Electrophysiol 2011; 22:922.
- Strandberg LS, Cui X, Rath A, et al. Congenital heart block maternal sera autoantibodies target an extracellular epitope on the α1G T-type calcium channel in human fetal hearts. PLoS One 2013; 8:e72668.
- Markham AJ, Rasmussen SE, Salmon JE, et al. Reactivity to the p305 Epitope of the α1G T-Type Calcium Channel and Autoimmune-Associated Congenital Heart Block. J Am Heart Assoc 2015; 4.
- Buyon JP, Winchester RJ, Slade SG, et al. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies. Arthritis Rheum 1993; 36:1263.
- Buyon J, Roubey R, Swersky S, et al. Complete congenital heart block: risk of occurrence and therapeutic approach to prevention. J Rheumatol 1988; 15:1104.
- Gordon P, Khamashta MA, Rosenthal E, et al. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol 2004; 31:2480.
- Jaeggi E, Laskin C, Hamilton R, et al. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants. J Am Coll Cardiol 2010; 55:2778.
- Reed JH, Jackson MW, Gordon TP. A B cell apotope of Ro 60 in systemic lupus erythematosus. Arthritis Rheum 2008; 58:1125.
- Kan N, Silverman ED, Kingdom J, et al. Serial echocardiography for immune-mediated heart disease in the fetus: results of a risk-based prospective surveillance strategy. Prenat Diagn 2017; 37:375.
- Stea EA, Routsias JG, Clancy RM, et al. Anti-La/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in an offspring. Arthritis Rheum 2006; 54:2228.
- Fritsch C, Hoebeke J, Dali H, et al. 52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block. Arthritis Res Ther 2006; 8:R4.
- Salomonsson S, Sonesson SE, Ottosson L, et al. Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 2005; 201:11.
- Strandberg L, Winqvist O, Sonesson SE, et al. Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block. Clin Exp Immunol 2008; 154:30.
- Clancy RM, Buyon JP, Ikeda K, et al. Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects. Arthritis Rheum 2005; 52:3079.
- Reed JH, Clancy RM, Lee KH, et al. Umbilical cord blood levels of maternal antibodies reactive with p200 and full-length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus. Arthritis Care Res (Hoboken) 2012; 64:1373.
- Sheth AP, Esterly NB, Ratoosh SL, et al. U1RNP positive neonatal lupus erythematosus: association with anti-La antibodies? Br J Dermatol 1995; 132:520.
- Acherman RJ, Friedman DM, Buyon JP, et al. Doppler fetal mechanical PR interval prolongation with positive maternal anti-RNP but negative SSA/Ro and SSB/La auto-antibodies. Prenat Diagn 2010; 30:797.
- Sirén MK, Julkunen H, Kaaja R, et al. Role of HLA in congenital heart block: susceptibility alleles in children. Lupus 1999; 8:60.
- Clancy RM, Marion MC, Kaufman KM, et al. Identification of candidate loci at 6p21 and 21q22 in a genome-wide association study of cardiac manifestations of neonatal lupus. Arthritis Rheum 2010; 62:3415.
- Meisgen S, Östberg T, Salomonsson S, et al. The HLA locus contains novel foetal susceptibility alleles for congenital heart block with significant paternal influence. J Intern Med 2014; 275:640.
- Clancy RM, Backer CB, Yin X, et al. Genetic association of cutaneous neonatal lupus with HLA class II and tumor necrosis factor alpha: implications for pathogenesis. Arthritis Rheum 2004; 50:2598.
- Stevens AM, Hermes HM, Rutledge JC, et al. Myocardial-tissue-specific phenotype of maternal microchimerism in neonatal lupus congenital heart block. Lancet 2003; 362:1617.
- Shiiya C, Ota M. Facial Rash, Fever, and Anemia in a Newborn. JAMA 2017; 317:2125.
- Silverman E, Jaeggi E. Non-cardiac manifestations of neonatal lupus erythematosus. Scand J Immunol 2010; 72:223.
- Neiman AR, Lee LA, Weston WL, Buyon JP. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. J Pediatr 2000; 137:674.
- Lee LA. Neonatal lupus: clinical features, therapy, and pathogenesis. Curr Rheumatol Rep 2001; 3:391.
- Peñate Y, Guillermo N, Rodríguez J, et al. Histopathologic characteristics of neonatal cutaneous lupus erythematosus: description of five cases and literature review. J Cutan Pathol 2009; 36:660.
- Ho SY, Esscher E, Anderson RH, Michaëlsson M. Anatomy of congenital complete heart block and relation to maternal anti-Ro antibodies. Am J Cardiol 1986; 58:291.
- Askanase AD, Friedman DM, Copel J, et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus 2002; 11:145.
- Chockalingam P, Jaeggi ET, Rammeloo LA, et al. Persistent fetal sinus bradycardia associated with maternal anti-SSA/Ro and anti-SSB/La antibodies. J Rheumatol 2011; 38:2682.
- Llanos C, Friedman DM, Saxena A, et al. Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus. Rheumatology (Oxford) 2012; 51:1086.
- Cuneo BF, Strasburger JF, Niksch A, et al. An expanded phenotype of maternal SSA/SSB antibody-associated fetal cardiac disease. J Matern Fetal Neonatal Med 2009; 22:233.
- Moak JP, Barron KS, Hougen TJ, et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 2001; 37:238.
- Buyon JP, Hiebert R, Copel J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31:1658.
- Falcini F, De Simone L, Donzelli G, Cerinic MM. Congenital conduction defects in children born to asymptomatic mothers with anti-SSA/SSB antibodies: report of two cases. Ann Ital Med Int 1998; 13:169.
- Houssiau FA, Lebacq EG. Neonatal lupus erythematosus with congenital heart block associated with maternal systemic lupus erythematosus. Clin Rheumatol 1986; 5:505.
- Hornberger LK, Al Rajaa N. Spectrum of cardiac involvement in neonatal lupus. Scand J Immunol 2010; 72:189.
- Nield LE, Silverman ED, Taylor GP, et al. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation 2002; 105:843.
- Nield LE, Silverman ED, Smallhorn JF, et al. Endocardial fibroelastosis associated with maternal anti-Ro and anti-La antibodies in the absence of atrioventricular block. J Am Coll Cardiol 2002; 40:796.
- Guettrot-Imbert G, Cohen L, Fermont L, et al. A new presentation of neonatal lupus: 5 cases of isolated mild endocardial fibroelastosis associated with maternal Anti-SSA/Ro and Anti-SSB/La antibodies. J Rheumatol 2011; 38:378.
- Ferrazzini G, Fasnacht M, Arbenz U, et al. Neonatal lupus erythematosus with congenital heart block and severe heart failure due to myocarditis and endocardititis of the mitral valve. Intensive Care Med 1996; 22:464.
- Kim KR, Yoon TY. A case of neonatal lupus erythematosus showing transient anemia and hepatitis. Ann Dermatol 2009; 21:315.
- Lynn Cheng C, Galbraith S, Holland K. Congenital lupus erythematosus presenting at birth with widespread erosions, pancytopenia, and subsequent hepatobiliary disease. Pediatr Dermatol 2010; 27:109.
- Lee LA, Sokol RJ, Buyon JP. Hepatobiliary disease in neonatal lupus: prevalence and clinical characteristics in cases enrolled in a national registry. Pediatrics 2002; 109:E11.
- Wei Sun, Yuan TM, Chen LH, Yu HM. Neonatal lupus erythematosus: three case reports and review of the Chinese literature. Clin Pediatr (Phila) 2010; 49:627.
- Wolach B, Choc L, Pomeranz A, et al. Aplastic anemia in neonatal lupus erythematosus. Am J Dis Child 1993; 147:941.
- Kanagasegar S, Cimaz R, Kurien BT, et al. Neonatal lupus manifests as isolated neutropenia and mildly abnormal liver functions. J Rheumatol 2002; 29:187.
- Boros CA, Spence D, Blaser S, Silverman ED. Hydrocephalus and macrocephaly: new manifestations of neonatal lupus erythematosus. Arthritis Rheum 2007; 57:261.
- Askanase AD, Izmirly PM, Katholi M, et al. Frequency of neuro-psychiatric dysfunction in anti-SSA/SSB exposed children with and without neonatal lupus. Lupus 2010; 19:300.
- Chen CC, Lin KL, Chen CL, et al. Central nervous system manifestations of neonatal lupus: a systematic review. Lupus 2013; 22:1484.
- Buyon JP, New York University School of Medicine, 2017, personal communication.
- Donofrio MT, Moon-Grady AJ, Hornberger LK, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation 2014; 129:2183.
- Glickstein JS, Buyon J, Friedman D. Pulsed Doppler echocardiographic assessment of the fetal PR interval. Am J Cardiol 2000; 86:236.
- Phoon CK, Kim MY, Buyon JP, Friedman DM. Finding the "PR-fect" solution: what is the best tool to measure fetal cardiac PR intervals for the detection and possible treatment of early conduction disease? Congenit Heart Dis 2012; 7:349.
- Silverman ED. Neonatal lupus. In: Textbook of pediatric rheumatology, Cassidy JT, Petty RE (Eds), WB Saunders, Philadelphia 2001. p.456.
- Williams C, Merchant WJ, Clark SM. Familial annular erythema--a rare dermatology diagnosis. Pediatr Dermatol 2011; 28:56.
- Saha A, Seth J, Mukherjee S, Basu S. Annular erythema of infancy: A diagnostic challenge. Indian J Pediatr Dermatol 2014; 15:147.
- Other factors
- CLINICAL MANIFESTATIONS
- Heart block
- Other cardiac abnormalities
- Other manifestations
- SCREENING AND SURVEILLANCE
- - Maternal screening
- - Fetal surveillance for heart block
- Postnatal testing
- DIFFERENTIAL DIAGNOSIS
- Rash without heart block
- Fetal bradycardia/heart block
- SUMMARY AND RECOMMENDATIONS